FGF13 Is a Novel Regulator of NF-κB and Potentiates Pathological Cardiac Hypertrophy.

Abstract

FGF13 is an intracellular FGF factor. Its role in cardiomyopathies has been rarely investigated. We revealed that endogenous FGF13 is up-regulated in cardiac hypertrophy accompanied by increased nuclear localization. The upregulation of FGF13 plays a deteriorating role both in hypertrophic cardiomyocytes and mouse hearts. Mechanistically, FGF13 directly interacts with p65 by its nuclear localization sequence and co-localizes with p65 in the nucleus in cardiac hypertrophy. FGF13 deficiency inhibits NF-κB activation in ISO-treated NRCMs and TAC-surgery mouse hearts, whereas FGF13 overexpression shows the opposite trend. Moreover, FGF13 overexpression alone is sufficient to activate NF-κB in cardiomyocytes. The interaction between FGF13 and p65 or the effects of FGF13 on NF-κB have nothing to do with IκB. Together, an IκB-independent mechanism for NF-κB regulation has been revealed in cardiomyocytes both under basal and stressful conditions, suggesting the promising application of FGF13 as a therapeutic target for pathological cardiac hypertrophy and heart failure.

• Authors: Jia Sun, Chao Niu, Weijian Ye, Ning An, Gen Chen, Xiaozhong Huang, Jianan Wang, Xixi Chen, Yingjie Shen, Shuai Huang, Ying Wang, Xu Wang, Yang Wang, Litai Jin, Weitao Cong, Xiaokun Li
• Journal: iScience (iScience) Vol. 23 Issue 10 Pg. 101627 (Oct 23 2020) ISSN: 2589-0042 [Electronic] United States
• PMID: 33089113 (Publication Type: Journal Article)
• Copyright: © 2020 The Author(s).